Interindividual variability in the effect of atazanavir and saquinavir on the expression of lymphocyte P-glycoprotein

Journal of Antimicrobial Chemotherapy

Volumn 60, Issue 1, 2007, Pages 61-67

  Chinn, Leslie W ^a   Gow, Jason M ^a   Tse, Man Ming ^b   Becker, Stephen L ^b   Kroetz, Deanna L ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Pacific Horizon Medical Group   (United States)

Author keywords

ABCB1; Antivirals; Protease inhibitors

Indexed keywords

ATAZANAVIR; GLYCOPROTEIN P; MESSENGER RNA; MULTIDRUG RESISTANCE PROTEIN 1; RITONAVIR; SAQUINAVIR;

ADULT; AGED; ARTICLE; CELL STRAIN HEK293; CONTROLLED STUDY; DRUG EFFECT; FEMALE; FLOW CYTOMETRY; GENETIC POLYMORPHISM; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; HUMAN EXPERIMENT; IN VITRO STUDY; INHIBITION KINETICS; LYMPHOCYTE; MALE; NORMAL HUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ATP-BINDING CASSETTE TRANSPORTERS; CELL LINE; HIV PROTEASE INHIBITORS; HUMANS; LYMPHOCYTES; OLIGOPEPTIDES; P-GLYCOPROTEIN; PYRIDINES; SAQUINAVIR;

EID: 34447578816     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkm135     Document Type: Article

References (53)

1. Clotet B. Strategies for overcoming resistance in HIV-1 infected patients receiving HAART. AIDS Rev 2004; 6: 123-30.
2. Levi J, Kates J. HIV: Challenging the health care delivery system. Am J Public Health 2000; 90: 1033-6.
3. Hays RD, Cunningham WE, Sherbourne CD et al. Health-related quality of life in patients with human immunodeficiency virus infection in the United States: Results from the HIV Cost and Services Utilization Study. Am J Med 2000; 108: 714-22.
4. Fridland A, Connelly MC, Robbins BL. Cellular factors for resistance against antiretroviral agents. Antivir Ther 2000; 5: 181-5.
5. Boffito M, Winston A, Owen A. Host determinants of antiretroviral drug activity. Curr Opin Infect Dis 2005; 18: 543-9.
6. Glavinas H, Krajcsi P, Cserepes J et al. The role of ABC transporters in drug resistance, metabolism and toxicity. Curr Drug Deliv 2004; 1: 27-42.
7. Leslie EM, Deeley RG, Cole SP. Multidrug resistance proteins: Role of P-glycoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue defense. Toxicol Appl Pharmacol 2005; 204: 216-37.
8. Ueda K, Cardarelli C, Gottesman MM et al. Expression of a full-length cDNA for the human "MDR1" gene confers resistance to colchicine, doxorubicin, and vinblastine. Proc Natl Acad Sci USA 1987; 84: 3004-8.
9. Litman T, Druley TE, Stein WD et al. From MDR to MXR: New understanding of multidrug resistance systems, their properties and clinical significance. Cell Mol Life Sci 2001; 58: 931-59.
10. Fromm MF. Importance of P-glycoprotein for drug disposition in humans. Eur J Clin Invest 2003; 33 Suppl 2: 6-9.
11. Krishna R, Mayer LD. Multidrug resistance (MDR) in cancer. Mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs. Eur J Pharm Sci 2000; 11: 265-83.
12. Fromm MF. Importance of P-glycoprotein at blood-tissue barriers. Trends Pharmacol Sci 2004; 25: 423-9.
13. Jones K, Bray PG, Khoo SH et al. P-glycoprotein and transporter MRP1 reduce HIV protease inhibitor uptake in CD4 cells: Potential for accelerated viral drug resistance? AIDS 2001; 15: 1353-8.
14. Mouly SJ, Paine MF, Watkins PB. Contributions of CYP3A4, P-glycoprotein, and serum protein binding to the intestinal first-pass extraction of saquinavir. J Pharmacol Exp Ther 2004; 308: 941-8.
15. Profit L, Eagling VA, Back DJ. Modulation of P-glycoprotein function in human lymphocytes and Caco-2 cell monolayers by HIV-1 protease inhibitors. AIDS 1999; 13: 1623-7.
16. Kim AE, Dintaman JM, Waddell DS et al. Saquinavir, an HIV protease inhibitor, is transported by P-glycoprotein. J Pharmacol Exp Ther 1998; 286: 1439-45.
17. Washington CB, Wiltshire HR, Man M et al. The disposition of saquinavir in normal and P-glycoprotein deficient mice, rats, and in cultured cells. Drug Metab Dispos 2000; 28: 1058-62.
18. Lee CG, Gottesman MM, Cardarelli CO et al. HIV-1 protease inhibitors are substrates for the MDR1 multidrug transporter. Biochemistry 1998; 37: 3594-601.
19. Perloff ES, Duan SX, Skolnik PR et al. Atazanavir: Effects on P-glycoprotein transport and CYP3A metabolism in vitro. Drug Metab Dispos 2005; 33: 764-70.
20. Lucia MB, Golotta C, Rutella S et al. Atazanavir inhibits P-glycoprotein and multidrug resistance-associated protein efflux activity. J Acquir Immune Defic Syndr 2005; 39: 635-7.
21. Ford J, Khoo SH, Back DJ. The intracellular pharmacology of antiretroviral protease inhibitors. J Antimicrob Chemother 2004; 54: 982-90.
22. Rendon A, Nunez M, Jimenez-Nacher I et al. Clinical benefit of interventions driven by therapeutic drug monitoring. HIV Med 2005; 6: 360-5.
23. Barry MG, Merry C, Lloyd J et al. Variability in trough plasma saquinavir concentrations in HIV patients - a case for therapeutic drug monitoring. Br J Clin Pharmacol 1998; 45: 501-2.
24. Bonfanti P, Valsecchi L, Parazzini F et al. Incidence of adverse reactions in HIV patients treated with protease inhibitors: A cohort study. Coordinamento Italiano Studio Allergia e Infezione da HIV (CISAI) Group. J Acquir Immune Defic Syndr 2000; 23: 236-45.
25. John L, Marra F, Ensom MH. Role of therapeutic drug monitoring for protease inhibitors. Ann Pharmacother 2001; 35: 745-54.
26. Back DJ, Khoo SH, Gibbons SE et al. Therapeutic drug monitoring of antiretrovirals in human immunodeficiency virus infection. Ther Drug Monit 2000; 22: 122-6.
27. Colombo S, Telenti A, Buclin T et al. Are plasma levels valid surrogates for cellular concentrations of antiretroviral drugs in HIV-infected patients? Ther Drug Monit 2006; 28: 332-8.
28. Kim RB. Drug transporters in HIV Therapy. Top HIV Med 2003; 11 136-9.
29. Geick A, Eichelbaum M, Burk O. Nuclear receptor response elements mediate induction of intestinal MDR1 by rifampin. J Biol Chem 2001; 276: 14581-7.
30. King JR, Kakuda TN, Paul S et al. Pharmacokinetics of saquinavir with atazanavir or low-dose ritonavir administered once daily (ASPIRE I) or twice daily (ASPIRE II) in seronegative volunteers. J Clin Pharmacol 2007; 47: 201-8.
31. Maffeo A, Bellomi F, Solimeo I et al. P-glycoprotein expression affects the intracellular concentration and antiviral activity of the protease inhibitor saquinavir in a T cell line. New Microbiol 2004; 27: 119-26.
32. Ronaldson PT, Lee G, Dallas S et al. Involvement of P-glycoprotein in the transport of saquinavir and indinavir in rat brain microvessel endothelial and microglia cell lines. Pharm Res 2004; 21: 811-8.
33. Williams GC, Knipp GT, Sinko PJ. The effect of cell culture conditions on saquinavir transport through, and interactions with, MDCKII cells overexpressing hMDR1. J Pharm Sci 2003; 92: 1957-67.
34. Park S, Sinko PJ. P-glycoprotein and mutlidrug resistance-associated proteins limit the brain uptake of saquinavir in mice. J Pharmacol Exp Ther 2005; 312: 1249-56.
35. Chandler B, Almond L, Ford J et al. The effects of protease inhibitors and nonnucleoside reverse transcriptase inhibitors on P-glycoprotein expression in peripheral blood mononuclear cells in vitro. J Acquir Immune Defic Syndr 2003; 33: 551-6.
36. Dupuis ML, Flego M, Molinari A et al. Saquinavir induces stable and functional expression of the multidrug transporter P-glycoprotein in human CD4 T-lymphoblastoid CEMrev cells. HIV Med 2003; 4: 338-45.
37. Perloff MD, von Moltke LL, Fahey JM et al. Induction of P-glycoprotein expression by HIV protease inhibitors in cell culture. AIDS 2000; 14: 1287-9.
38. Dussault I, Lin M, Hollister K et al. Peptide mimetic HIV protease inhibitors are ligands for the orphan receptor SXR. J Biol Chem 2001; 276: 33309-12.
39. Schote AB, Turner JD, Schiltz J et al. Nuclear receptors in human immune cells: Expression and correlations. Mol Immunol 2007; 44 1436-45.
40. Albermann N, Schmitz-Winnenthal FH, Z'Graggen K et al. Expression of the drug transporters MDR1/ABCB1, MRP1/ABCC1, MRP2/ABCC2, BCRP/ABCG2, and PXR in peripheral blood mononuclear cells and their relationship with the expression in intestine and liver. Biochem Pharmacol 2005; 70: 949-58.
41. Owen A, Chandler B, Back DJ et al. Expression of prognane-X-receptor transcript in peripheral blood mononuclear cells and correlation with MDR1 mRNA. Antivir Ther 2004; 9: 819-21.
42. Andreana A, Aggarwal S, Gollapudi S et al. Abnormal expression of a 170-kilodalton P-glycoprotein encoded by MDR1 gene, a metabolically active efflux pump, in CD4+ and CD8+ T cells from patients with human immunodeficiency virus type 1 infection. AIDS Res Hum Retroviruses 1996; 12: 1457-62.
43. Meaden ER, Hoggard PG, Maher B et al. Expression of P-glycoprotein and multidrug resistance-associated protein in healthy volunteers and HIV-infected patients. AIDS Res Hum Retroviruses 2001; 17: 1329-32.
44. Cauda R, Lucia MB, Ortona L et al. A new, striking morphological alteration of P-glycoprotein expression in NK cells from AIDS patients. Immunol Lett 1998; 60: 19-21.
45. Gollapudi S, Gupta S. Human immunodeficiency virus I-induced expression of P-glycoprotein. Biochem Biophys Res Commun 1990; 171: 1002-7.
46. Lucia MB, Cauda R, Landay AL et al. Transmembrane P-glycoprotein (P-gp/P-170) in HIV infection: Analysis of lymphocyte surface expression and drug-unrelated function. AIDS Res Hum Retroviruses 1995; 11 893-901.
47. Kroetz DL, Pauli-Magnus C, Hodges LM et al. Sequence diversity and haplotype structure in the human ABCB1 (MDR1, multidrug resistance transporter) gene. Pharmacogenetics 2003; 13: 481-94.
48. Buss N, Snell P, Bock J et al. Saquinavir and ritonavir pharmacokinetics following combined ritonavir and saquinavir (soft gelatin capsules) administration. Br J Clin Pharmacol 2001; 52 255-64.
49. Pellegrin I, Breilh D, Birac V et al. Pharmacokinetics and resistance mutations affect virologic response to ritonavir/ saquinavir-containing regimens. Ther Drug Monit 2001; 23: 332-40.
50. Regazzi MB, Villani P, Maserati R et al. Pharmacokinetic variability and strategy for therapeutic drug monitoring of saquinavir (SQV) in HIV-1 infected individuals. Br J Clin Pharmacol 1999; 47: 379-82.
51. Autar RS, Boffito M, Hassink E et al. Interindividual variability of once-daily ritonavir boosted saquinavir pharmacokinetics in Thai and UK patients. J Antimicrob Chemother 2005; 56: 908-13.
52. Hoetelmans RM, Meenhorst PL, Mulder JW et al. Clinical pharmacology of HIV protease inhibitors: Focus on saquinavir, indinavir, and ritonavir. Pharm World Sci 1997; 19: 159-75.
53. Valer L, de Mendoza C, Soriano V. Predictive value of drug levels, HIV genotyping, and the genotypic inhibitory quotient (GIQ) on response to saquinavir/ritonavir in antiretroviral-experienced HIV-infected patients. J Med Virol 2005; 77: 460-4.